Zydus Receives Final Approval From The USFDA For Emtricitabine Tablets

Zydus Cadila has received final approval from the USFDA to market Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg (US RLD: Truvada® Tablets) and tentative approval for the strengths of 100 mg/ISO mg, 133 mg/200 mg, and 167 mg/250 mg, ofthe same drug.

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in the body so the immune system can work better. This will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has 281 approvals and has so far filed over 386 ANDAS since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.260.5 as compared to the previous close of Rs. 249.7. The total number of shares traded during the day was 84496 in over 2742 trades.

The stock hit an intraday high of Rs. 263.3 and intraday low of 240.6. The net turnover during the day was Rs. 21071662.-Equity Bulls